Viability of primary human pigment epithelium cells and muller-glia cells after intravitreal ziv-aflibercept and aflibercept

Viability of primary human pigment epithelium cells and muller-glia cells after intravitreal ziv-aflibercept and aflibercept

Author de Andrade, Gabriel Costa Autor UNIFESP Google Scholar
Wertheimer, Christian Google Scholar
Eibl, Kirsten Google Scholar
Wolf, Armin Google Scholar
Kampik, Anselm Google Scholar
Rodrigues, Eduardo Buchele Autor UNIFESP Google Scholar
Farah, Michel Eid Autor UNIFESP Google Scholar
Haritoglou, Christos Autor UNIFESP Google Scholar
Abstract Purpose: The aim of this study was to access the safety profiles of 2 fusion proteins with anti-vascular endothelial growth factor action (ziv-aflibercept and aflibercept) on retinal pigment epithelium cells and Muller-Glia cells in culture by assessing cell viability post drug exposure. Methods: Primary human retinal pigment epithelium cells (pRPE) and Muller-Glia cells (Mio-M1) were exposed to the clinical standardized concentrations of ziv-aflibercept (25 mg/mL) and aflibercept (40 mg/mL). Progressively higher concentrations of NaCI (300, 500, 1,000, 1,500, 2,000, 5,000, and 10,000 mosm/kg) were also applied to cells to assess the possibility of potentiating hyperosmotic cytotoxity effect. The study was applied to measure pRPE and Mio-M1 viability by a tetrazolium dye-reduction assay (XTT). Results: Cell viability of both pRPE and Mio-M1 presented no significant changes after exposure of ziv-aflibercept and aflibercept. Progressive NaCI concentrations did not significantly alter cell viability. The exposure to the negative control of 75 mu L/mL of dimethyl sulfoxide showed significant reduction in cell viability. Conclusions: At clinical doses, neither ziv-aflibercept nor aflibercept caused any significant reduction in cell viability in vitro. Furthermore, injection solutions of NaCI with higher osmolality caused no significant reduction in cell viability. (C) 2017 S. Karger AG, Basel
Keywords Ziv-Aflibercept
Aflibercept
ToxicityMacular Degeneration
Inhibitor
Growth
Language English
Date 2016
Published in Ophthalmologica. Basel, v. 236, n. 4, p. 223-227, 2016.
ISSN 0030-3755 (Sherpa/Romeo, impact factor)
Publisher Taylor & Francis Inc
Extent 223-227
Origin https://doi.org/10.1159/000452677
Access rights Closed access
Type Article
Web of Science ID WOS:000392559700007
URI http://repositorio.unifesp.br/handle/11600/49275

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account